Studies Find Limited Support For Genotyping-Guided Warfarin Dosing
This article was originally published in The Gray Sheet
Executive Summary
The overall message of three trials published recently in The New England Journal of Medicine: “This pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing,” according to an editorial also in NEJM.